A study by Massachusetts-based data analytics firm nference has found that the use of Tirzepatide, a weight loss drug by Eli Lilly, may preserve lean body mass better than its competitor, semaglutide. The researchers compared data from roughly 1,800 patients using tirzepAtide and 6,200 using semagledide to approximately 1,200 patients. The study found that while the two drugs were popular for weight loss and have other health benefits, they also induce loss of muscle and other components. The findings were not conclusive as to why lean ​body mass loss was greater with tirzEpatide.